Their chemical structures create different resistance profiles, so comparable broad-spectrum coverage does not mean they are interchangeable in every situation. Cefepime and meropenem should be compared against the resistant Gram-negative pathogens suspected in the infection. This distinction helps clinicians choose empiric therapy that better matches the anticipated bacterial threat while avoiding assumptions based only on antibiotic class.
Meropenem provides strong activity against many anaerobic bacteria, which can broaden its usefulness when anaerobes are part of the suspected infectious process. That feature distinguishes it from cefepime in therapeutic comparisons. Recognizing this difference helps clinicians align empiric treatment with the range of organisms they need to cover rather than focusing only on resistant Gram-negative pathogens.
Activity against Pseudomonas aeruginosa is an important comparison point because this organism can be a concern in serious infections involving resistant Gram-negative bacteria. Evaluating how each agent fits the suspected pathogen profile supports more deliberate empiric choices. Subsequent culture-directed assessment can then determine whether the initial selection remains appropriate for the identified organism.
Empiric selection should begin with the organisms most likely to cause the serious infection, especially when resistant Gram-negative pathogens are a concern. Clinicians can then weigh each drug’s resistance profile, activity against Pseudomonas aeruginosa, and, for meropenem, coverage of many anaerobes. This approach connects initial treatment with the infection’s anticipated microbiology rather than choosing solely by drug class.
Cultures provide the microbiologic information needed to move from empiric treatment toward culture-directed therapy. Results can clarify whether the suspected pathogen is covered by the selected agent and whether the original comparison remains relevant. Using that information makes treatment more specific and supports antimicrobial stewardship, particularly when broad-spectrum therapy was started because resistance was initially possible.
The comparison supports stewardship by encouraging clinicians to match broad-spectrum treatment with the organisms and resistance concerns relevant to a serious infection. Cefepime’s profile, meropenem’s anaerobic coverage, and activity against Pseudomonas aeruginosa provide distinct factors for review. Reassessing therapy with culture information helps maintain an evidence-based choice while promoting safer management of severe bacterial infections.